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ABSTRACT 
 
Melanoma is the most lethal type of skin cancer and originates in melanocytes, cells that 
produce the pigment melanin.  Five year survival rates are particularly high for this type 
of cancer if the tumor is diagnosed and treated early.  However, survival rates decline 
significantly if the tumor is allowed to metastasize.  Frequency of melanoma has risen 
over recent years, especially in young people.  Much progress has been made in treating 
melanoma; however, tumor recurrence is frequently seen in patients after treatment has 
concluded. The leading genes that are found to be mutated in melanoma are v-Raf murine 
sarcoma viral oncogene homolog B1 (BRAF), neuroblastoma RAS viral (v-ras) oncogene 
homolog (NRAS), phosphatase and tensin homolog deleted on chromosome ten (PTEN) 
and cyclin dependent kinase inhibitor 2A (CDKN2A) which belong to the MAPK 
(Mitogen-activated protein kinase/Extracellular signal-regulated kinases) pathway, the 
phosphoinositide 3’ kinase (PI3K)/AKT pathway or the INK4/ARF locus. Together, 
these two pathways and locus form a signaling network that work in tandem to promote 
cell proliferation, migration, invasion and metastasis.  Recent breakthroughs in treating 
melanoma include the advent of BRAF inhibitors, but patients often experience tumor 
recurrence.  Research conducted to understand acquired BRAF inhibitor resistance 
suggests that tumor regrowth is due to continued activation of the MAPK and PI3K/AKT 
pathways through BRAF independent routes.  Therefore, new treatments, which can be 
personalized, are being developed that target multiple components of both of these 
pathways.  The epigenetic causes of melanoma are vast and are just recently becoming 
clear.   
 
 Introduction 
Skin cancer presents in many different forms but the most lethal type is melanoma 
which was accountable for 76,250 new 
year (Arozarena et al. 2011
mortality rates are expected to con
Melanoma begins in melanocyte cells which produce the skin pigmentation 
molecule melanin.  The irregularities of these cells first present as benign nevus (mole) 
and can therefore go unnoticed by a patient.  A melanoma lesion can develop anywhere 
on the skin but also in areas that a patient would typically not think to inspect for 
melanoma including the mucous membranes lining the mouth, n
(Sosman 2012).  Once a patient has noticed such a mole, it is imperative for them to see 
either their primary care physician or 
a dermatologist as soon as possible 
because early detection is critical to 
curing and surviving melanoma.  A 
common diagnostic tool by primary 
care physicians and dermatologists is 
the melanoma acronym ABCDE in 
which A stands for asymmetr
borders which are irregular, C color 
changes, D diameter and E for 
evolution meaning that the
2 
Figure 1. The diagnostic ABCDEs of mela
Adapted from Melanoma:Signs and Symptoms, In 
American Academy of Dermatology, n.d., Retrieved 
April 17, 2013, from http://www.aad.org/skin
conditions/dermatology-a-to-z/melanoma/signs
symptoms/melanoma-signs-and 
symptoms#.UW7khsqNB-S 
cases and 8,000 deaths in the United States 
).  Despite an already high frequency, the incidence and 
tinue to rise (van den Hurk et al. 2012).   
ose, and genital areas 
y, B 
 mole 
noma.  
-
-
each 
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continues to change appearance (Sosman 2012).  Different types of melanoma, which 
include superficial spreading, nodular, acral lentiginous, and lentigo maligna, are 
categorized by altered presentations of the ABCDEs of melanoma including different 
color, shape and location on the body (van den Hurk et al. 2012). 
The occurrence of melanoma in 1973 in the United States was 6.8 in 100,000 
people and that number raised to 20.1 in 100,000 from 2003 to 2007 (Tuong et al. 2012).  
The age range of those diagnosed with melanoma is quite expansive with some patients 
being in the under twenty years old age range while some patients are over eighty years 
old.  Based on data in the United States for the years 2003 to 2007 the mortality rate was 
highest (24.1%) for those between the ages of seventy-five and eighty-four years old and 
declines as the age range declines (Tuong et al. 2012). It was estimated that 8,700 
patients died of melanoma in the United States in 2010 (Tuong et al. 2012).  Patients who 
have previously been diagnosed with melanoma are at a greater risk of developing 
melanoma again usually within five years of initial diagnosis.  A recent study found that 
the five year risk of developing a second primary melanoma was 11.4% and 30.9% for 
developing a third primary melanoma within five years of initial diagnosis (Tuong et al. 
2012).  These risk factors are increased if the patient has a familial history of melanoma.  
Melanoma patients may be at risk for developing the cancer again but their chance of 
surviving the disease again has increased since the 1970s.  The five year survival rates 
have increased from 78.1% in men and 86.9% in women from 1975 to 1977 to 91.1% in 
men and 95.1% in women from 1999 to 2006 (Tuong et al. 2012).  This is most likely 
due to an overall greater understanding of the cellular mechanisms of melanoma and the 
advent of better therapies since the 1970s. 
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A major risk factor for melanoma development is ultraviolet (UV) light exposure.  
In response to prolonged UV exposure, DNA is damaged.  Usually DNA repair 
mechanisms can repair this damage but sometimes the damage goes undetected or it is 
repaired incorrectly.  Risk factors for developing melanoma due to excessive UV light 
exposure include one’s skin color, occupation, recreational activities and number of 
sunburns in one’s lifetime.   
Melanoma occurs more frequently in Caucasians than non-Caucasians and 
individuals with red hair and fair skin are at the greatest risk of developing melanoma 
(Mitra et al. 2012).  Skin color is determined by the ratio of the two types of melanin; the 
red-yellow pheomelanin and the brown-black eumelanin (Mitra et al. 2012).  Overall 
melanin production is regulated by the melanocortin 1 receptor (MC1R) (Mitra et al. 
2012).  When MC1R is activated it stimulates the production of eumelanin and decreased 
MC1R activation is associated with pheomelanin production (Mitra et al. 2012).  
Therefore, individuals with the red hair/fair skin phenotype have increased amount of 
pheomelanin and decreased MC1R activity stemming from particular polymorphisms in 
the MC1R gene.  The eumelanin pigment is able to absorb UV rays thereby defending 
against UV induced damage (Mitra et al. 2012).  Since red haired/fair skinned individuals 
have more pheomelanin than eumelanin, their skin is vulnerable to UV induced damage 
causing these individuals to have a higher tendency to develop melanoma (Mitra et al. 
2012).  
One’s genetics are a contributing factor in developing melanoma but so are the 
choices that we make on a daily basis such as our job and recreational activities.  Those 
who work outside, such as construction workers, are at a greater risk of developing 
 5 
melanoma due to the prolonged sunlight exposure.  People who hike, bike, or do any 
other sort of outdoor activities frequently are also at risk of being diagnosed with 
melanoma sometime in their lifetime.  Where one chooses to live can also put them at a 
greater threat for melanoma.  Melanoma frequency is greater in locales that are exposed 
to more intense UV such as those at higher altitude or lower latitude (Tuong et al. 2012).  
Another risk factor for melanoma is the number of sunburns one has had during their 
lifetime (Tuong et al. 2012).  A recent study showed that those who had more than 5 
sunburns in their life had a twofold increase in regards to their risk of developing 
melanoma (Tuong et al. 2012).   All of these risks can be decreased with the use of 
sunscreen.  Today’s media has been helpful in educating the public of the risk of 
prolonged UV exposure and how this risk is easily remedied through the use of 
sunscreen. 
The number of younger people, especially young women, diagnosed with 
melanoma is greater than any other type of cancer (Hausauer et al. 2011).  This is most 
likely due to the growing prevalence of artificial UV exposure through the use of tanning 
beds which has increased over the last decade (Tuong et al. 2012).  Despite the known 
risk of UV exposure, people continue to use artificial tanning beds as well as natural 
sunlight to tan.  In fact, it has been estimated that about thirty million people use indoor 
tanning in the United States with 2.3 million of those being adolescents (Tuong et al. 
2012).  The correlation between UV exposure and melanoma has garnered much media 
attention prompting the beauty industry to release products such as self-tanning lotions 
and spray tans.  Hopefully these products will lure people away from the dangers of a 
traditional tanning bed.   
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There are four different stages of melanoma: Stage I or IIA, Stage IIB or IIC, 
Stage III and Stage IV (Sosman 2012).  Stage I or IIA disease is classified by the size of 
the tumor being less than four millimeters thick with no evidence of ulceration or two 
millimeters thick with ulceration (Sosman 2012).  This is the early stage of disease and as 
such 70% to 90% of cases can be cured with surgery alone.  Stage IIB or IIC is 
characterized by a thicker tumor, 2.1 to four millimeters thick and with ulceration or four 
or more millimeters thick no matter the ulceration status (Sosman 2012).  Like Stage I or 
IIA, Stage IIB or IIC is still a localized disease.  However, Stage IIB or IIC patients are at 
a greater risk of eventual recurrence and therefore usually have another form of therapy 
in addition to surgical removal of tumor (Sosman 2012).  Stage III is the first stage in 
which the tumor shows evidence of metastasis with cancer invading the lymphatic 
channels that border the tumor or to the nearby lymph nodes (Sosman 2012).  The 
melanoma then metastasizes to more distant locations in the body which is a 
characteristic of Stage IV disease, or advanced disease (Sosman 2012). 
Once the tumor has metastasized it is often fatal.  Metastatic melanoma accounts 
for 75% of skin cancer related deaths and a worldwide estimated 48,000 fatalities per 
year and the incidence of melanoma is on the rise (Nikolaev et al. 2012).  Not 
surprisingly, prognosis decreases with each stage that the melanoma enters into.  Survival 
for stage I is very high with a five year survival rate of 91% to 95% and a 10 year 
survival rate of 83% to 88% (Tuong et al. 2012).  However, survival rate drop drastically 
for stage II melanoma with a five year survival of 45% to 79% and a ten year survival of 
32% to 64% (Tuong et al. 2012).  This decrease is due to the appearance of ulceration at 
stage II which is a poor prognostic sign (Tuong et al. 2012).  In stage III of melanoma the 
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cancer begins to metastasize and the patient’s short and long term survival depends on the 
amount and location of metastasis.  The five year survival rate of stage III melanoma is 
30% to 70% (Tuong et al. 2012).  Stage IV is the most deadly stage with a survival of 
10% to 20% (Tuong et al. 2012).  Once melanoma has reached the metastatic stage, the 
average survival time is six to nine months (Tuong et al. 2012).  The most common 
location for stage IV metastasis is the brain and once the tumor has spread to the brain the 
average survival time is three to four months (Tuong et al. 2012).  A recent study of 
6,953 metastatic melanoma patients found that the brain metastases contributed to the 
death of 94.5% of the group (Tuong et al. 2012). 
Understanding the genetic causes of melanoma is essential to developing new 
treatments and helping patients fight this deadly disease.  The many genes that have, to 
date, been found to be commonly mutated in melanoma can be split into two classes: the 
proto-oncogenes and the tumor suppressor genes.  When the protein products of 
oncogenes are conducting their normal function, they are of no harm to the cell.  
However, a mutated oncogene that produces an inactive protein can lead to cancer.  On 
the other hand, the role of a tumor suppressor protein is to protect the cell from a 
cancerous path.  If the tumor suppressor protein is no longer functional in this capacity 
the cell may become cancerous.  Many of oncogenes and tumor suppressor genes are 
involved in the pathways that help to regulate cellular growth and the cell cycle. 
An emerging area of research within melanoma is exploring the epigenetic causes 
of melanoma.  Epigenetics are changes in gene expression due to alterations that are not 
made to the DNA sequence.  This includes modifications to the DNA methylation state, 
histone modifications and non-coding RNAs.  The epigenetic causes of melanoma are 
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only in the early stages of research and it will take many years for this research to lead to 
a functioning therapy for patients.   
Melanoma treatments vary depending on the size of the tumor and metastasis 
status.  For a primary tumor in Stage I or IIA or Stage IIB or IIC the primary treatment is 
surgical removal of the tumor.  Treatment options for metastatic melanoma include 
immunotherapy, targeted therapy, chemotherapy and radiation (Sosman 2012).  Recent 
advances in the fields of immunotherapy and targeted therapy have made these treatment 
options favorable over chemotherapy and radiation among oncologists (Sosman 2012).  
The two types of immunotherapy that have been developed to treat melanoma are high 
dose interleukin-2 (IL-2) and ipilimumab (Sosman 2012).  IL-2 is a cytokine that induces 
the proliferation of T-cells, thereby stimulating the immune system to target the tumor.  
Ipilimumab is a monoclonal antibody, specifically a cytotoxic T-lymphocyte antigen four 
(CTLA4) antagonistic antibody, which induces the T-cell immune response against 
melanoma tumors (Ribas 2011).  Many melanoma cell lines contain a specific mutation 
in one gene (BRAF) and the product of this mutated gene is at least partially responsible 
for the growth of the tumor.  The mutated BRAF protein is the target of targeted therapy 
drugs such as Vemurafenib, also known as PLX4032 (Sosman 2012).  The use of 
Vemurafenib has caused tumors with BRAF mutations to shrink; however, even with 
continued treatment, the tumor can begin to grow again (Sosman 2012). 
Chemotherapy has been effective, although the results of such treatments are not 
long lasting (Prickett et al. 2011) and with the recent advances of other treatment options 
(immunotherapy and targeted therapy), chemotherapy is no longer the initial treatment 
option utilized by oncologists (Sosman 2012).  Chemotherapeutic agents used to treat 
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melanoma patients include dacarbazine and temozolomide (Sosman 2012).  Dacarbazine 
acts by alkylating and cross-linking DNA (Tarhini and Agarwala 2006) throughout all 
cell cycle phases, which results in DNA function disruption, cell cycle arrest and 
eventually apoptosis.  Temozolomide is an analog of dacarbazine and acts by methylating 
guanine, which leads to DNA replication inhibition (Tarhini and Agarwala 2006).  
Radiation therapy is another treatment option available to melanoma patients.  A 
frequent site of melanoma metastasis is the brain.  There are some locations within the 
brain that can be treated surgically; however, there are many areas in the brain are 
inoperable (Sosman 2012).  To treat these locations, radiation therapy is often used either 
as radiosurgery where a specific site can be targeted (Sosman 2012).  If the tumors are 
too widespread throughout the brain, whole brain radiation therapy is utilized (Sosman 
2012). 
Melanoma, once it has metastasized, is a highly aggressive and deadly form of 
skin cancer.  We know much about the genetics of melanoma, which has led to the 
development of many treatment options.  However, these treatments aren’t long lasting 
and aren’t effective against every patient’s specific mutations.  Hallmark mutations of 
melanoma and current research to develop therapeutic targets for these mutations will be 
further discussed in this literature review.  Recent research epigenetic causes of 
melanoma and potential therapies will also be further discussed. 
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The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 
Pathway is Highly Mutated in Melanoma 
The Mitogen-activated protein kinase/Extracellular signal-regulated kinases 
(MAPK) signaling pathway is an important pathway in melanoma given that the two 
most commonly mutated genes in melanoma, v-Raf murine sarcoma viral oncogene 
homolog B one (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog 
(NRAS), are involved in this pathway (Dankort et al. 2009).  When the MAPK pathway 
is functioning normally, proliferation, survival, senescence and differentiation are 
regulated (Arozarena et al. 2011).  However, if components of the pathway are altered 
and therefore not functioning properly, the pathway is likely to be constitutively 
activated.  The constant activation of this pathway leads to uncontrolled proliferation and 
survival leading to cancer.  It is therefore highly important to understand this pathway 
and how all the different components interact with each other in order to comprehend 
melanoma proliferation.  A further understanding of this pathway could potentially lead 
to sources of new treatments.  This interaction between elements of the MAPK pathway 
and the consequences of mutation will be analyzed in the following sections. 
Oncogenic mutations in NRAS, a member of the RAS family of proteins, are seen 
in approximately 25% of melanoma patients (Arozarena et al. 2011).  The RAS family of 
proteins, which also includes HRAS and KRAS, are G proteins that are activated 
downstream of receptors for growth factors, cytokines and hormones (Arozarena et al. 
2011).  Many of the most common NRAS mutations impair the enzyme’s ability to 
hydrolyze guanosine triphosphate (GTP), resulting in a preserved active state (Greger et 
al. 2012).  The most common mutation causes a substitution of leucine to glutamine at 
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position sixty-one (Smalley and McArthur 2012). Oncogenic mutations of KRAS and 
HRAS have been observed in melanoma, but only at a rate of 1% to 2% (Kim 2010).  
Mouse models have shown that oncogenic mutations in KRAS and HRAS can lead to the 
development of melanoma, but it is yet unclear why mutations in these RAS proteins are 
so rarely clinically observed (Kim 2010).  The RAS proteins activate the serine threonine 
specific protein kinase RAF family which consists of ARAF, BRAF and CRAF 
(Arozarena et al. 2011).  Mutations in BRAF are found in approximately 40% to 60% of 
melanoma patients, with 90% of those mutations consisting of a glutamic acid 
substitution for valine at position 600 (V600E) (Arozarena et al. 2011).  This substitution 
is located within the active site of BRAF (Kaplan et al. 2011) and causes destabilization 
of the inactive kinase form; thus, the active kinase is the preferred conformation (Smalley 
and Flaherty 2009).  Nonetheless, other mutations causing a constitutively active BRAF 
have been described, about one hundred total, but most of these mutations are considered 
rare (Heidorn et al. 2010).  The most common BRAF mutation other than BRAFV600E 
causes a lysine substitution for valine at position 600 (V600K) (Smalley and McArthur 
2012).  Mitogen and extracellular signal regulated protein kinase kinase (MEK1 and 
MEK2) is phosphorylated and activated by RAF, which then activates extracellular signal 
regulated protein kinase (ERK1 and ERK2) (Arozarena et al. 2011).  Since BRAF 
mutations in melanoma are so commonly seen, therapeutics that target these mutations 
have been developed and patients that receive these therapies do see clinical 
improvement (Krauthammer et al. 2012).  However, melanoma tumors commonly 
reoccur after the BRAF targeted treatment has ended (Arozarena et al., 2011). Therefore, 
it is important to understand the role of BRAF in metastasis. 
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The downstream consequences of mutated BRAF also appear to play a role in 
generating malignant melanoma (Arozarena et al. 2011).  For example, the cyclic 
guanosine monophosphate (cGMP)-specific phosphodiesterase PDE5A gene was found 
to be downregulated in oncogenic BRAF melanoma cells through upregulation of the 
transcription factor BRN2 (also known as POU class 3 homeobox 2) (Arozarena et al. 
2011).  When PDE5A is downregulated, levels of the second messenger cGMP increase, 
causing levels of intracellular calcium to increase (Arozarena et al. 2011).  It is believed 
that increased intracellular levels of calcium aid in cancerous cell invasion by stimulating 
myosin light chain two phosphorylation and thereby prompting cellular contractility 
(Arozarena et al. 2011).  Arozarena et al. (2011) was indeed able to demonstrate that 
increased intracellular calcium can drive melanoma invasion by inducing contractility.  
However, oncogenic NRAS mutations do not induce invasion through PDE5A 
(Arozarena et al. 2011) so NRAS driven metastasis must be driven by different 
mechanisms than oncogenic BRAF. 
 
The PI3K/AKT Pathway is a Major Signaling Pathway Involved in Melanoma 
Tumorigenesis 
The PI3K/AKT pathway is another important signaling pathway in the 
progression of melanoma.  This pathway can be activated by a variety of receptors 
including receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs), 
which in turn activates phosphoinositide 3’ kinase (PI3K) (Davies 2012).  PI3K can also 
be activated by the RAS family of proteins thereby linking the PI3K/AKT pathway to the 
MAPK pathway (Kim, 2010).  PI3K converts Phosphatidylinositol 4, 5-bisphosphate 
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(PIP2) to the intracellular second messenger Phosphatidylinositol 3, 4, 5-trisphosphate 
(PIP3) (Aguissa-Toure´ and Li 2012).  PIP3 then binds to the Pleckstrin homology (PH) 
domain of Serine–threonine protein kinase AKT, also known as protein kinase B (PKB), 
assisting in the translocation of AKT to the plasma membrane (Madhunapantula and 
Robertson 2011).  There, AKT is activated by phosphorylation by the membrane bound 
phosphoinositide dependent kinase one (PDK1) (Madhunapantula and Robertson 2011).  
An activated AKT in turn translocates to the cytoplasm and/or nucleus to activate or 
inhibit its various targets (Courtney et al. 2010).  Some of the inhibitory targets of AKT 
include the proapoptotic Bcl-2 family members BAD (Bcl-2-associated death promoter) 
and BAX (Bcl-2-associated X protein) (Courtney et al. 2010).  Another AKT substrate is 
mouse double minute two homolog (MDM2) which is an E3-ubiquitin protein ligase that 
targets the tumor suppressor protein p53 for degradation, thereby leaving cell 
proliferation pathways unchecked (Yajima et al. 2012).  Mammalian target of rapamycin 
(mTOR) is a serine/threonine kinase that is also targeted for activation by AKT (Populo 
et al. 2012)  mTOR is a component of two structurally and functionally distinct 
complexes: mTORC1 and mTORC2 (Populo et al. 2012).  mTORC1 is composed of the 
proteins mTOR, raptor, mLST8 and two negative regulators, is activated by and can 
suppress AKT signaling, and its downstream targets include proteins involved in cell 
cycle regulation, ribosome biogenesis and protein synthesis (Populo et al. 2012).  
mTORC1 can also be activated as a result of downstream ERK signaling, a member of 
the MAPK pathway (Populo et al. 2012).  This serves as a converging point for 
PI3K/AKT and MAPK signaling that could potentially be beneficially exploited.  On the 
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other hand, mTOR, rictor, mSIN1 and mLST8 compose mTORC2 which stimulates AKT 
signaling and regulates the small GTPases RAC and Rho (Populo et al. 2012). 
The PI3K/AKT pathway becomes problematic for the cell when it is constantly or 
prematurely activated, which could occur through many different mechanisms including 
activation of RTKs that initiate the signaling cascade and AKT activation (Kim 2010).  In 
fact, it was recently shown that increased activation of the AKT3 isoform in melanoma 
can be due to mutations (Davies 2012) or DNA copy gain in the AKT3 gene (Kim 2010).  
However, these types of alterations are quite rare and have only been identified in 
approximately 1.5% of melanoma samples (Davies 2012).  Over activation of the 
pathway could also be caused by alterations in the PI3K gene including mutations and 
copy number changes; but, mutations in the PI3K gene are known to be rare (Vredeveld 
et al. 2012).  In fact, missense mutations in the catalytic subunit of PI3K were identified 
in 3% of melanoma cell lines and clinical samples (Davies 2012).  Instead, constitutive 
activation of the PI3K/AKT pathway is more frequently caused by alterations in negative 
regulators. 
Phosphatase and tensin homolog deleted on chromosome ten (PTEN), also known 
as mutated in multiple advanced cancers (MMAC1) and TGF-β regulated and epithelial 
cell-enriched phosphatase (TEP1) (Mounir et al. 2009), is involved in the regulation of 
the PI3K/AKT pathway and is the second most mutated tumor suppressor in melanoma 
(Jacob et al. 2009).  In addition to mutations that results in protein truncation or loss of 
catalytic activity, loss of heterozygosity, chromosomal loss, microRNA dependent 
mechanisms, and transcriptional silencing due to promoter methylation have also been 
shown to cause loss of PTEN in melanoma (Davies 2012).  PTEN can function either as a 
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lipid phosphatase or as a protein phosphatase (Wu et al. 2003).  It is through PTEN’s 
lipid phosphatase activity that it negatively regulates the PI3K/AKT pathway by 
converting PIP3 back to PIP2 (Aguissa-Toure´ and Li 2012). This decrease in intracellular 
PIP3 levels leads to inhibition of the downstream pathway and therefore apoptosis.  When 
PTEN is mutated and not functioning properly, the PI3K/AKT pathway is not regulated, 
leading to uncontrolled cell proliferation.   
The protein phosphatase activity of PTEN was recently linked with inhibition of 
protein translation (Mounir et al. 2009).  Mounir et al. (2009) discovered that upon PTEN 
inactivation in human melanoma cells the phosphorylation of the alpha subunit of 
eukaryotic translation initiation factor 2 (eIF2) had decreased, thereby decreasing protein 
synthesis.  Reintroduction of wild type PTEN led to an increase in eIF2α phosphorylation 
and protein synthesis (Mounir et al. 2009).  This newly discovered function of PTEN is 
another example of its tumor suppressive capabilities that, in conjunction with its 
inhibition of the PI3K/AKT pathway, makes this protein so important in melanoma.  
Mutations in PTEN can lead to melanoma, but so can mutations in genes for 
proteins that interact with PTEN.  One such gene is phosphatidylinositol-3, 4, 5-
triphosphate-dependent RAC exchange factor 2 (PREX2) (Fine et al. 2009, Berger et al. 
2012).  PREX2 is a guanine nucleotide exchange factor (GEF) that inhibits the lipid 
phosphatase activity of PTEN, consequently stimulating activity of the PI3K/AKT 
pathway (Fine et al. 2009) and was found by Berger et al. (2012) to be mutated in 14% of 
107 human melanomas.  Ras-related C3 botulinum toxin substrate 1 (RAC1) is also 
activated through the GEF function of PREX2 (Fine et al. 2009).  RAC1 is a member of 
the Rho protein family, which functions similarly to the RAS protein family 
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(Krauthammer et al. 2012).  The Rho proteins are monomeric GTPases that transmit 
extracellular signals from cell surface receptors to intracellular signaling pathways, such 
as the MAPK and PI3K/AKT pathways, to regulate cell cycle progression and gene 
regulation (Hodis et al. 2012).  RAC1’s most characterized function is regulating 
cytoskeletal rearrangement; therefore, RAC1 is involved in cellular adhesion, migration 
and invasion (Hodis et al. 2012).  Hodis et al. (2012) and Krauthammer et al. (2012) 
recently identified RAC1 as a driver mutation leading to the development of melanoma.  
RAC1 has been shown to be recurrently mutated with a strong UV signature, which 
involves a cytosine to thymine transition, in non-malignant and malignant melanomas 
(Krauthammer et al. 2012).  Hodis et al. (2012) identified a mutational hotspot in the 
RAC1 gene that results in a conversion of proline twenty-nine to a serine.  This mutation 
destabilizes the GDP bound state of the protein and favors that GTP bound state resulting 
in a constitutively active RAC1 (Hodis et al. 2012).  A constitutively active RAC1 would 
constantly be transferring a signal; for example, to proceed through the cell cycle without 
the activation of a receptor.  Thus, RAC1 serves to connect the MAPK pathway to the 
PI3K/AKT pathway through PREX2. 
 
Mutated cell surface receptors are also involved in further activation of the MAPK and 
PI3K/AKT pathway 
Proto-oncogene c-Kit (KIT) encodes for cKIT tyrosine kinase receptor for stem 
cell factor (SCF) that is found to be mutated in approximately 20% of melanoma tumors 
(Went et al. 2004) making it the fourth most common mutation found in melanoma (Kim 
2010).  However, most melanomas with oncogenic KIT are found on parts of the body 
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that are not typically exposed to environmental UV radiation such as the soles of the feet 
or subungual sites (acral melanomas), the mucous membranes (mucosal melanomas) and 
the pigmented cells of the eye (uveal melanomas) (Smalley and McArthur 2012).  KIT is 
a receptor for stem cell factor, which upon binding causes dimerization, 
autophosphorylation of KIT, and further activation of downstream signaling pathways, 
such as the MAPK and PI3K/AKT pathways (Carvajal et al. 2011).  Constitutive 
activation of this receptor, however, does not lead to increased proliferation of 
melanocytes (Alexeev and Yoon 2006).  Instead, evidence suggests that constitutive KIT 
signaling induces cell migration, specifically toward the epidermis (Alexeev and Yoon 
2006).  Therefore, overactive KIT signaling supports malignancy, clarifying why 
mutations in the c-KIT gene are so commonly seen in melanoma tissue (Alexeev and 
Yoon 2006).   
Recent research has shown that G protein coupled receptors can also be mutated 
in melanoma and contribute to further activation of the MAP Kinase signaling pathway 
(Prickett et al. 2011).  Specifically, the group II metabotropic glutamate receptor three 
gene (GRM3) was implicated in higher melanoma tumor growth rate, greater number of 
melanoma colonies, and increased cellular migration (Prickett et al. 2011).  Also, 
activating mutations in some regulatory subunits of GPCRs, including the G-protein 
alpha subunits GNAq and GNA11 have been identified in 35% and 45% of uveal 
melanoma (Davies 2012).  Mutations in these subunits can cause impaired GTPase 
activity and thus, constitutive signaling (Smalley and McArthur 2012).  Tyrosine kinase 
receptors are also responsible for initiating MAPK and PI3K/AKT signaling cascades and 
many have been shown to be mutated in melanoma.  For example, in a study of seventy-
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nine melanoma tissue samples, the RTK ERBB4, a member of the epidermal growth 
factor receptor family, was mutated in 19% of the samples (Prickett et al. 2009).  Several 
ERBB4 mutations that were identified resulted in increased kinase activity and 
phosphorylation of ERK and AKT.  Cell growth was decreased following small hairpin 
RNA (shRNA) mediated knockdown and addition of the pan-ERBB pharmacologic 
inhibitor lapatinib (GW2016) further cementing ERBB4’s role in promoting cell 
proliferation signals.  Unquestionably, there are many more receptors that commence 
MAPK and PI3K/AKT signaling and are not yet identified; but, given their function more 
research should be completed in this area. 
 
The INK4/ARF Locus That Produces the Tumor Suppressor Gene CDKN2A and 
CDKN2B is Frequently Mutated in Melanoma  
A tumor suppressor locus that is found to be mutated in 25% to 40% of familial 
melanoma cases is the INK4b/ARF/INK4 locus on chromosome nine (van den Hurk et al. 
2012).  This locus contains the tumor suppressor gene cyclin dependent kinase inhibitor 
2A (CDKN2A), which through alternative splicing produces a transcript for p16INK4a and 
p14ARF, and the CDKN2B gene which produces the p15INK4b transcript (van den Hurk et 
al. 2012).   
All three of the protein products from this locus are inhibitors of proteins essential 
to pathways that regulate the cell cycle (Laud et al. 2006).  p16INK4a and p15INK4b bind to 
and cause a conformational changes to cyclin dependent kinase 4 (CDK4) and CDK6 
thus blocking their binding to D-type cyclins (Kim and Sharpless 2006).  D-type cyclin 
proteins phosphorylate retinoblastoma (Rb) family members to promote cell cycle 
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Figure 2. The INK4/ARF Locus produces 3 
tumor suppressor transcripts:p15INK4b, 
p16INK4a, and ARF (p14ARF) that are involved 
in regulating the cell cycle.  Adapted from “The 
Regulation of INK4/ARF in Cancer and Aging,” 
by Kim, W.Y. and Sharpless, N.E., 2006, Cell. 
127, p. 265. Copyright 2006 by Elsevier Inc. 
progression (Kim and Sharpless 2006).  
However, p16INK4a and p15INK4b mediated 
silencing of CDK4 and CDK6 results in 
hypophosphorylated Rb, and therefore G1 
cell cycle arrest (Kim and Sharpless 2006).  
Additionally, p14ARF can arrest the cell 
cycle in both the G1 and the G2/M phases 
by inhibiting the destruction of the tumor 
suppressor p53 via MDM2 sequestration (Laud et al. 2006).  If any of these three proteins 
are damaged, the cell cycle checkpoints that they regulate will be disregarded, and the 
mutant cell will continue to proliferate. 
Human cancers commonly contain homozygous deletions of the entire INK4/ARF 
locus that abolishes expression of all three protein products (Kim and Sharpless 2006).  It 
is therefore debatable which locus member, if any, acts as the main tumor suppressor 
(Kim and Sharpless 2006).  However, the region that creates the transcript for p16INK4a is 
the most commonly mutated region of the locus, with mutations found in 25% of familial 
melanomas and 50% of sporadic melanomas (Muthusamy et al. 2006).  Many of these 
mutations in p16INK4a region of the locus spare the p14ARF and p15INK4b locus regions 
(Kim and Sharpless 2006).  Epigenetic silencing by promoter methylation of p16INK4a is 
commonly seen in many cancer types (Kim and Sharpless 2006).  On the other hand, 
epigenetic silencing of p15INK4b is rarely observed in cancer (Kim and Sharpless 2006).  
A small number of human cancers have been reported that harbor inactivation of p14ARF 
without loss of p15INK4b and p16INK4a (Kim and Sharpless 2006).  However, mice 
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knockout studies have shown that mice with p14ARF and p16INK4a knocked out were more 
susceptible to developing cancer than mice with one member of the locus knocked out 
(Kim and Sharpless 2006).  This combination knockout of the locus has also been 
observed in melanoma cell lines (Kim and Sharpless 2006).  Although evidence may 
indicate that p16INK4a or a combination of p14ARF and p16INK4a are the main tumor 
suppressors of the INK4b/ARF/INK4 locus, much remains to be understood of the 
regulation and interactions of this locus. 
The INK4b/ARF/INK4 pathway can also be disrupted by alterations in the 
proteins that the INK4/ARF protein products regulate, such as CDK4 and MDM2.  
Activating mutations in CDK4 that disrupt p16INK4a binding are seen in rare familial 
melanomas (Muthusamy et al. 2006).  Overexpression of CDK4 and MDM2 through 
amplification of their locus on chromosome twelve has been observed in about 50% of 
melanomas (Muthusamy et al. 2006).  However, when CDK4 and MDM2 are 
overexpressed, the INK4/ARF locus remains unchanged (Muthusamy et al. 2006).  This 
suggests that CDK4 and MDM2 amplification can substitute for INK4/ARF locus loss of 
function (Muthusamy et al. 2006).   
 
The Signaling Network of MAPK Pathway, PI3K/AKT Pathway and INK4/ARF 
Locus Crosstalk to Induce Tumorigenesis and Further Metastasis 
In order to fully understand melanoma, we must first begin with understanding 
the mechanisms behind melanomagenesis.  Many nevi that could potentially become 
cancerous harbor activated BRAFV600E mutations (Cheung et al. 2008, Madhunapantula 
and Robertson 2009, Vredeveld et al. 2012).  However, some of these nevi do not 
 develop into melanoma because mutant BRAF
inhibition and cellular senescence through increased MAPK pathway in nevi (Cheung et 
al. 2008).  This observation suggests that there is a required cooperati
event(s) to induce tumorigenesis (Che
event is phosphorylation of BRAF
AKT3 can phosphorylate BRAF
BRAFV600E activity, thereby decreasing MAPK p
This decrease in MAPK 
pathway activity promotes 
proliferation and, therefore, 
tumor progression (Cheung 
et al. 2008). 
Tumor suppressor 
loss could also account for 
tumorigenesis in nevi 
expressing activated  
BRAFV600E.  Recent evidence 
by Chen et al. (2012) 
suggested that BRAFV600E 
negatively regulate the PI3K/AKT pathway by binding to 
However, loss of the tumor suppressor PTEN was able to override the BRAF
induced negative regulation and allow activation of the PI3K/AKT pathway.  Vredeveld 
et al. (2012) was also able to show that PTEN loss and BRAF mu
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Figure 3. The MAPK and PI3K/AKT Pathways
from “RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling 
in Malignant Melanoma Progression and Therapy,” By 
Yajima, I. et al., 2011, Dermatology Research and Practice
2012, p. 2. Copyright 2012 by Ichiro Yajima et al.
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tumorigenesis.  Their results demonstrated tumor progression in cells with the BRAFV600E 
mutation followed by silencing of PTEN by shRNAs (Vredeveld et al. 2012).  Another 
tumor suppressor also involved in perpetuating cellular senescence in nevi is p16INK4a 
(Schopfer et al. 2006).  Given its potential role in cellular senescence, loss of p16INK4a 
could contribute to tumorigenesis (Schopfer et al. 2006).  It is therefore possible that loss 
of tumor suppressor is the rate limiting event in melanomagenesis (Vredeveld et al. 
2012). 
PTEN inactivation has also been linked with melanomagenesis through oncogenic 
HRAS and INK4a/ARF loss (Kim 2010, Nogueira et al. 2010).  Mouse models showed 
that mice that were PTEN and INK4a/ARF deficient and did not have oncogenic RAS 
mutations did not develop melanoma (Kim 2010).  On the other hand, mice that did have 
oncogenic RAS mutations along with PTEN and INK4a/ARF loss did develop melanoma 
with some metastases (Kim 2010).  Moreover, oncogenic RAS-INK4a/ARF deficient 
mice with PTEN loss demonstrated earlier melanoma onset than oncogenic RAS-
INK4a/ARF deficient mice with wild type PTEN (Nogueira et al. 2010).  These results 
suggest that loss of PTEN, oncogenic RAS and INK4a/ARF locus loss all cooperate 
together to induce tumorigenesis.  These findings are surprising given the function 
redundancy of RAS activation and PTEN loss (Kim 2010, Nogueira et al. 2010). 
Melanoma is especially deadly once it has metastasized to other areas of the body 
such as lymph nodes, lungs and the brain.  It is therefore critical that researchers 
comprehend the molecular mechanisms responsible for metastatic tumor growth.  A key 
event in metastasis is tissue invasion (Matsuoka et al. 2009).  In order for this to occur, 
extracellular matrix (ECM) components must be proteolytically cleaved by the matrix 
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metalloproteinase (MMP) family of enzymes (Matsuoka et al. 2009).  MMP expression 
levels have been shown to correlate with tumor invasiveness, and various MMPs have 
been shown to be expressed in melanoma cells (Matsuoka et al. 2009).  Expression of 
MMPs are, in part, controlled by activation of both MAPK and PI3K/AKT pathways; 
therefore, both pathways are implicated in this metastatic mechanism (Matsuoka et al. 
2009).   
PTEN loss and oncogenic BRAFV600E mutation have also been implicated, not just 
in tumorigenesis, but also in metastasis.  Dankort et al. (2009) discovered, using a mouse 
model, that the BRAFV600E mutation alone is not enough to induce malignant progression.  
PTEN silencing and mutated BRAF are seen together in 20% of human melanomas 
(Dankort et al. 2009) thus Dankort et al. (2009) investigated if this combination 
contributes to malignancy.  Mice that possessed activated BRAF and silenced PTEN 
showed malignant lesions in the face, flank, tail skin, draining and iliac lymph nodes and 
lungs with invasion into the subcutaneous tissue, suggesting that activated BRAF and 
silenced PTEN induce a greater amount of metastatic tumors throughout the body. 
The combination of PTEN loss, oncogenic RAS and loss of the INK4a/ARF locus 
has also been shown to influence the invasive potential of primary melanoma tumors 
(Kim 2010, Nogueira et al. 2010).  Experiments by Nogueira and colleagues showed that 
PTEN expression negatively correlated with invasion in oncogenic RAS-INK4a/ARF 
deficient mice.  Evidence showed that this increase in invasiveness also correlated with a 
switch among activated AKT isoforms, in particular AKT3 to AKT2 (Nogueira et al. 
2010).  These results are surprising given the long held belief that PTEN preferentially 
phosphorylates and activates AKT3 in melanoma and not AKT2 (Madhunapantula and 
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Robertson 2009).  However, over activated AKT2 has been associated with ovarian and 
pancreatic cancer (Madhunapantula and Robertson 2011) so it could stand to reason that 
it could also play in role in melanoma. 
 
Treatments Targeting the Signaling Network of MAPK pathway, PI3K/AKT 
Pathway and INK4/ARF Locus 
Understanding BRAF chemotherapeutic resistance 
As previously discussed, BRAF inhibitors are a widely used treatment against 
melanoma.  However, the effects of BRAF inhibitors are sustained for an average six to 
seven months, and many patients see recurrent tumor growth within one year of 
beginning BRAF inhibitor treatment (Davies 2012).  These observations suggest that the 
melanoma cells have developed a resistance to BRAF inhibition.  In fact, evidence has 
shown that treatment with one BRAF inhibitor can cause resistance to a different BRAF 
inhibitor (Villanueva et al. 2010).  Therefore, it is vital to understand the mechanisms 
behind BRAF inhibitor resistance in order to develop future treatments. 
A secondary mutation in BRAF during the evolution of melanoma cells could 
account for the BRAF inhibitor resistance.  However, recent evidence has shown that 
BRAF resistant cells do not harbor secondary BRAF mutations (Nazarian et al. 2010).  
Therefore, factors other than BRAF are most likely involved in acquired BRAF 
resistance. 
One possible cause of resistance to BRAF inhibitors in melanoma cells is due to 
the MAPK pathway being activated in a BRAF independent manner.  The reactivation of 
the MAPK pathway could potentially start with activation of the receptor.  Platelet 
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derived growth factor receptor β (PDGFRβ) is a receptor tyrosine kinase that is 
responsible for activation of the MAPK pathway (Nazarian et al. 2010).  This receptor 
was recently shown to be overexpressed with elevated activation levels in BRAF resistant 
melanoma cells, thereby leading to activation of the MAPK pathway (Nazarian et al. 
2010).  In the same study, NRAS protein levels and activation were found to be elevated 
in cells resistant to BRAF inhibitors (Nazarian et al. 2010).  Knockdown of PDGFRβ and 
NRAS caused cell cycle arrest and/or apoptosis, thus linking factors upstream of BRAF 
to acquired BRAF inhibitor resistance (Nazarian et al. 2010).   
ERK, a downstream target of BRAF, remains activated in BRAF inhibitor 
resistant cells following shRNA mediated BRAF knockdown and treatment with a high 
dose of a BRAF inhibitor, suggesting that ERK is being activated by a factor other than 
BRAF (Villanueva et al. 2010).  It is possible that the other RAF isoforms, ARAF and 
CRAF, could be responsible for the BRAF independent activation of ERK (Villanueva et 
al. 2010).  Villanueva et al. (2010) showed that ERK phosphorylation decreased 
following knockout of all three RAF isoforms, suggesting that ARAF and CRAF are in 
fact responsible activation of the MAPK pathway and contribute to BRAF inhibitor 
resistance.  Experiments by Heidorn et al. (2010) and Kaplan et al. (2011) demonstrated a 
potential CRAF dependent mechanism by which ERK continues to be phosphorylated 
following treatment with BRAF inhibitors.  Their results suggest that following BRAF 
inhibition, BRAF binds to and activates CRAF leading to activation of ERK and its 
downstream target.  However, the BRAF and CRAF binding only occurred in the 
presence of oncogenic NRAS suggesting that BRAF inhibitors could cause tumor 
reemergence in patients with oncogenic NRAS mutations.  When the oncogenic NRAS 
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melanoma cells were treated with the MEK1/2 inhibitor, ERK1/2 and its downstream 
targets were not activated by phosphorylation (Kaplan et al. 2011) suggesting that MEK 
inhibitors would be a more prudent treatment for tumors with activated NRAS than 
BRAF inhibitors. 
Evidence has shown that the MAPK pathway can be activated by other 
mechanisms in BRAF inhibitor resistant cells.  For example, ERK can be activated by 
other factors that do not require BRAF signaling such as Mitogen-activated protein 
kinase 8/cancer osaka thyroid oncogene (MAP3K8/COT) (Johannessen et al. 2010).  
MAP3K8 expression is downregulated melanocytes with oncogenic BRAF mutations 
compared to wild type melanocytes (Johannessen et al. 2010).  BRAF inhibitor resistant 
cells and wild type melanocytes have similar expression levels of MAP3K8 further 
supporting MAP3K8’s role in driving BRAF inhibitor resistance in melanoma cells 
(Johannessen et al. 2010).   
Current research has indicated that BRAF inhibitor resistance may be due, in part 
to AKT3 signaling (Shao and Aplin 2010, Villanueva et al. 2010).  Shao and Aplin 
(2010) showed that apoptosis in melanoma cells following treatment with PLX4720, a 
BRAF inhibitor that binds near the adenosine triphosphate (ATP) binding site of BRAF, 
was due to upregulation of the pro-apoptotic proteins B-cell lymphoma 2 modifying 
factor (BMF) and B-cell lymphoma two interacting mediator extra-long isoform (BIM-
EL) (Shao and Aplin 2010).  BIM-EL, and its other isoforms BIM-L (long) and BIM-S 
(short), promote apoptosis by binding to and antagonizing various anti-apoptotic proteins, 
including myeloid cell leukemia one (Mcl-1) (Paraiso et al. 2011).  Increased expression 
of Mcl-1 rendered melanoma cells resistant to BRAF inhibition induced apoptosis, and 
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knockdown of Mcl-1 made cells susceptible to apoptosis (Shao and Aplin 2010, Kaplan 
et al. 2011).  Using a mutant of AKT3 that is constitutively activated, Shao and Aplin 
(2010) were able to show that AKT3 signaling is involved in rendering melanoma cells 
resistant to BRAF inhibition induced apoptosis by blocking the upregulation of the pro-
apoptotic genes BIM-EL and BMF.  Expression of constitutively active AKT3 was also 
able to partially protect Mcl-1 knockdown cells from apoptosis (Shao and Aplin 2010).  
BIM expression was also recently demonstrated to be regulated by PTEN in cells that are 
resistant to PLX4720.  Paraiso et al. (2011) exhibited that BIM expression in increased in 
PLX4720 resistant cells that also express wild type PTEN, but BIM expression decreases 
when PTEN expression is lost.  Given the connection between BRAF inhibitor resistance 
and AKT3 signaling it would stand to reason that therapeutically targeting both of these 
pathways would lead a decrease in BRAF inhibitor resistance and therefore stop tumor 
progression. 
 
Targeting the MAPK pathway and the PI3K/AKT pathway individually show 
improvement in disease progression 
MEK inhibition is also a therapeutic target (Flaherty et al. 2012).  A MEK1 and 
MEK2 inhibitor, trametinib, also known as GSK1120212, developed by 
GlaxoSmithKline, has already shown tumor regression in mice and in patients with 
BRAFV600E and BRAFV600K  mutations in phase I and phase II clinical trials (Flaherty et 
al. 2012).  Recently, the results from the phase 3 clinical trials were released and the data 
is promising (Flaherty et al. 2012).  A total of 322 patients participated in the trials and 
some were given trametinib, while others were given chemotherapy of either dacarbazine 
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or paclitaxel (Flaherty et al. 2012).  Although, the patients from the chemotherapy group 
were allowed to switch to the trametinib group if they showed progression of the disease 
(Flaherty et al. 2012).  Results showed that progression free survival and the six month 
survival rate are improved with trametinib treatment (Flaherty et al. 2012).   
Despite the development of BRAF and MEK inhibitors, an efficient treatment for 
oncogenic NRAS has yet to be created (Kwong et al. 2012, Posch et al. 2013).  The lack 
of NRAS targeted therapeutics is, in part, due to NRAS’s affinity for GTP (Posch et al. 
2013).  The high intracellular GTP concentrations thus provide a barrier in isolating a 
small molecule that can which can block NRAS-GTP binding (Posch et al. 2013).  
Difficulties in developing a treatment for NRAS mutant tumors could also be due to 
NRAS’s ability to activate signaling cascades for both the MAPK and PI3K/AKT 
pathways.  MEK and BRAF inhibitors show little to no benefit in NRAS mutant tumors 
(Kwong et al. 2012).   Therefore, recent research has been focusing on designing a 
treatment to either directly or indirectly target NRAS.  For example, Kwong et al. (2012) 
performed computational modeling using an inducible conditional genetically engineered 
mouse (GEM) model to ascertain drug combinations that could simulate RAS inhibition.  
It was found that pharmacological inhibition of MEK, using either trametinib 
(GSK1120212) or selumetinib (AZD6244) and the CDK4 inhibitor PD-0332991, in vivo 
resulted in tumor regression (Kwong et al. 2012). 
In addition to inhibitors that target components of the MAPK pathway, many 
pharmaceuticals have been developed that target various elements of the PI3K/AKT 
pathway, including inhibitors for PI3K, mTORC1, dual mTORC1/mTORC2, dual 
PI3K/mTOR and AKT (Courtney et al. 2010).  Rapamycin and its analogs inhibit mTOR 
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in mTORC1, but not mTORC2, by forming a complex with FKBP12 which, in turn, 
binds to the FKBP12-rapamycin binding domain (Courtney et al. 2010).  ATP 
competitive inhibitors bind to the kinase domain of mTOR in both mTOR complexes 
(Courtney et al. 2010).  Theoretically, mTORC2 inhibition would be more effective than 
mTORC1 inhibition because mTORC2 regulates AKT (Courtney et al. 2010).  Indeed, 
early mice models have shown a greater proliferation inhibition with ATP competitive 
inhibitors than rapamycin (Courtney et al. 2010).  PI3K and mTOR belong to related 
kinase protein families and, their catalytic domains are, therefore, structurally similar 
(Courtney et al. 2010).  Researchers have been able to exploit this similar structure to 
develop dual PI3K/mTOR inhibitors, which, since these drugs target all PI3K isoforms 
and mTORC1/mTORC2, they would effectively shut down PI3K/AKT pathway signaling 
(Courtney et al. 2010).  However, testing the effects of complete PI3K/AKT signaling is 
imperative; consequently, many of these dual PI3K/mTOR inhibitors are currently in the 
beginning phases of clinical trials (Courtney et al. 2010).  Overall, PI3K/AKT pathway 
inhibitors have displayed modest results in early experiments (Courtney et al. 2010).  
Understanding  why only modest results have been seen will be vital for the future of 
PI3K/AKT pathway inhibitors. 
 
Combination therapy targeting both the MAPK pathway and PI3K/AKT pathway displays 
heightened results 
Many components of the MAPK pathway and PI3K/AKT pathway are commonly 
seen mutated together in melanoma, such as oncogenic BRAF and loss of PTEN 
(Vredeveld et al. 2012).  Therefore, recent research into developing new melanoma 
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treatments has focused on targeting both the MAPK and PI3K/AKT pathways in 
combination.  Several of these experiments concentrate on elucidating which 
combination of MAPK and PI3K/AKT inhibitors will be most advantageous. 
Experiments by Vredeveld et al. (2012) exhibited that inhibition of elements from 
both MAPK and PI3K/AKT pathways was more beneficial than inhibition of just one 
pathway.  BRAFV600E melanoma cell lines that were treated with Pi-103, an inhibitor of 
PI3K and mTOR kinases, showed increased p15INK4B expression and therefore, cell cycle 
arrest (Vredeveld et al. 2012).  However, when these cells were also treated with the 
BRAFV600E inhibitor PLX4720, cell death was observed via cleavage of caspase three 
(Vredeveld et al. 2012).  Treatment with just PLX4720 showed varying results with some 
cells surviving even when treated with a high dose of PLX4720 (Vredeveld et al. 2012).  
Combined PLX4720 and Pi-103 was able to eradicate this resistant population 
(Vredeveld et al. 2012).  Therefore, simultaneous targeting of BRAFV600E and 
PI3K/mTOR kinases may be a treatment option for BRAF inhibitor resistant tumors.  
Similar results have also been observed in BRAFV600E cells that are resistant to the BRAF 
inhibitor dabrafenib (GSK2118436) and contain NRAS and MEK mutations (Greger et 
al. 2012).  These cells showed increased cell death when treated with dabrafenib and the 
MEK inhibitor trametinib (GSK1120212) (Greger et al. 2012).  However, inhibition of 
cell growth was heightened with the addition of the PI3K/mTOR kinase inhibitor 
GSK2126458 to treatment with dabrafenib and trametinib (Greger et al. 2012).  Shi et al. 
(2011) also observed greater levels of apoptosis, not just cell growth inhibition, in cells 
that were treated with MEK1/MEK2 (AZD6244/Selumetinib), PI3K (BEZ235) and 
mTORC1/2 (AZD8055) inhibitors, than cells that were treated with BRAF 
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(vemurafenib), PI3K and mTORC1/2 inhibitors.  The above experiments demonstrate 
that combined targeting of MAPK and PI3K components leads to greater cell cycle arrest 
and apoptosis in BRAF inhibitor resistant cells than targeting only one pathway. 
As previously discussed, an effective treatment for NRAS mutant melanoma 
tumors remain elusive (Kwong et al. 2012, Posch et al. 2013).  However, recent research 
has suggested a new way of targeting oncogenic NRAS tumors.  In vivo and in vitro 
experiments by Posch et al. (2013) demonstrated that treatment with a MEK1/MEK2 
inhibitor (JTP-74057, PD325901) and inhibitors for either PI3K (GDC-0941 
bismesylate), AKT (GSK690693), mTORC1 (rapamycin), and mTORC1/mTORC2 
(PP242) resulted in increased cell death in NRAS mutant melanoma cells than treatment 
with a MEK inhibitor alone.  In addition, cell death was even further decreased via 
apoptosis when MEK, PI3K and mTORC1/mTORC2 inhibitors were used in conjunction 
(Posch et al. 2013).  Thus, combination targeting of MAPK and PI3K/AKT pathways 
may be a viable treatment option for NRAS mutant melanoma tumors. 
 
Epigenetics is a Promising Field for Advances in Simple Diagnostic Tools and 
Personalized Treatments 
Researchers have recently begun investigating possible epigenetic causes to 
diseases, including cancer.  Epigenetics are changes to the genome that does not alter the 
primary DNA sequence.  This includes DNA methylation, histone modifications and non-
coding RNAs, which have all recently been implicated in melanoma.   
Recent research by Hou and colleagues demonstrated a connection between the 
BRAFV600E mutation and changes in methylation state of specific genes.  In response to 
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BRAF knockdown, some genes are either hyper or hypomethylated when compared to 
their wild type methylation levels (Hou et al. 2012).  Many of these genes are involved in 
biological pathways such as tissue development, cell proliferation, differentiation, cell 
death, DNA replication, recombination and repair making them prime suspects to aid in 
tumorigenesis (Hou et al. 2012).  Two of the genes that were identified to be 
hypomethylated by BRAFV600E signaling and therefore overexpressed, FYVE RhoGEF 
and PH domain-containing protein 1 (FGD1) and High-mobility group protein B2 
(HMGB2), have previously been shown to be directly involved in the proliferation or 
invasion of melanoma cells further supporting the results (Hou et al. 2012).  The 
mechanism behind hypomethylated genes in BRAFV600E signaling remains unknown; 
however, DNA methyltransferase I and histone methyltransferase EZH2 are 
overexpressed in BRAFV600E mutants, indicating that these two methyltransferases may 
be involved in establishing hypermethylation in BRAFV600E signaling (Hou et al. 2012). 
The genome of melanoma is overall hypomethylated, but the amount of global 
hypomethylation is not significant enough to differentiate between melanoma and benign 
nevus (Lian et al. 2012).  Instead, it is more prudent to examine local hypermethylation or 
hypomethylation at specific genes (Lian et al. 2012).  However, investigating gene 
specific methylation changes is not practical in a clinical setting so Lian et al. (2012) 
compared the epigenome of melanoma and benign nevus samples and found that the 
global levels of 5-hydroxymethylcytosine (5-hmC) was decreased in primary and 
metastatic melanomas.  5-hmC is converted by the ten-eleven translocation (TET) family 
of DNA hydroxylases from 5-methylcytosine (5-mC) which is a key epigenetic marker 
for numerous biological processes (Lian et al. 2012).  It was also discovered that 5-hmC 
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levels have further diagnostic value in that 5-hmC levels were greater in stage I 
melanoma than stage II and III melanomas (Lian et al. 2012).  Next,  the researchers 
sought how exactly the decreased levels of 5-hmC are established.  Since the TET family 
of enzymes is responsible for the conversion of 5-mC to 5-hmC, they believed that these 
enzymes would be downregulated in melanomas.  A key co-factor in this reaction is α-
ketoglutarate which is produced by the isocitrate dehydrogenases, an enzyme family that, 
due to its indirect role in producing 5-hmC, would also be downregulated in melanoma.  
Lian et al. (2012) did, in fact, find that all members of the TET protein family and 
isocitrate dehydrogenase 2 (IDH2) had decreased expression in melanoma samples, and 
that when these proteins are overexpressed, 5-hmC levels increase and tumor growth and 
invasion are suppressed.  The findings by Lian et al. (2012) that 5-hmC is an epigenetic 
marker in melanoma could have diagnostic and therapeutic benefits.  An assay could 
potentially be developed as a diagnostic tool and classify a tumor into the various stages 
of melanoma.  A possible therapy could also be created that would increase 5-hmC given 
the results by Lian et al (2012)  that restoration of 5-hmC decreased tumor growth, 
decreased invasion and increased tumor free survival. 
As previously discussed, DNA methyltransferase I (Dnmt1), along with the 
related DNA methyltransferase 3b (Dnmt3b), have been linked to tumorigenesis, but no 
link has been found between DNA methyltransferase 3a (Dnmt3a) until the current 
research by Deng and colleagues.  Deng et al. (2009) discovered that Dnmt3a depletion 
drastically reduced tumor growth in subcutaneous melanoma and colony growth in 
metastatic lung melanoma using a mouse model.  Microarray analysis also showed that 
many genes are dysregulated in response to Dnmt3a depletion including genes involved 
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in immunity and defense, developmental processes and cell cycle (Deng et al. 2009).  The 
immunity and defense genes that were overexpressed upon Dnmt3a depletion included 
sixteen class I and class II major histocompatibility complex (MHC) genes, class II major 
histocompatibility complex transactivator (CIITA) and five chemokines (Deng et al. 
2009).  In order for a tumor to dodge the host immune system and thereby infiltrate 
healthy cells, the MHC genes are downregulated by CIITA (Deng et al. 2009).  Tumor 
penetration can also be achieved by either down or upregulation of chemokines, 
molecules that aid T cells in identifying host and foreign cells (Deng et al. 2009).  
Upregulation of these genes in Dnmt3a depleted cells indicates that downregulation of 
these genes may be a key mechanism in Dnmt3a facilitated melanoma tumorigenicity 
(Deng et al. 2009). 
Another area of epigenetics that has clinical significance is modifications to 
histones.  Different functional groups can be attached to histones that either cause DNA 
to be wound more tightly around histones, thereby silencing this area of the genome, or 
groups can be added that increase the repulsion between histones and DNA, allowing the 
transcription machinery easier access to the genome region.  Recently, Ceol et al. (2011) 
discovered a possible histone modification that can lead to the development of melanoma 
that also contributes to tumor proliferation.  They reasoned that recurrent copy number 
variations could result in increased expression of oncogenes leading to the formation of 
tumors.  Using zebrafish as model organisms, they found that when a particular region on 
chromosome one was recurrently amplified, it resulted in accelerated melanoma tumor 
formation.  This region on chromosome one corresponded with the gene SET domain, 
bifurcated 1 (SETDB1) which codes for an enzyme that trimethylates histone H3 lysine 
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nine thus repressing its target genes.  In their experiments using zebrafish, melanomas 
that were expressing higher levels of SETDB1 were more aggressive and invasive than 
wild type tumors. Whereas wild type and mutant tumors contained similar levels of 
BRAFV600E, indicating that SETDB1 does not increase tumor growth by altering BRAF.  
Since their evidence suggested that the BRAF gene is not the target of SETDB1, they set 
out to discover which genes SETDB1 is targeting for methylation.  Interestingly, they 
found that SETDB1 was bound to HOX genes.  They also analyzed human melanoma 
tissues for overexpression of SETDB1 and found that 5% of normal melanocytes, 15% of 
benign naevi and 70% of malignant melanomas contained increased levels of SETDB1.  
Given these results, a simple measure of SETDB1 level could be a melanoma predictor.  
One of the most current and complex fields of epigenetics is the study of 
microRNA (miRNA) and its role in disease, particularly cancer (Howell et al. 2010).  
miRNAs are small (19-24 nucleotides long), single stranded non-coding RNAs that bind 
to the 3’ untranslated region of messenger RNA (mRNA) thereby blocking translation or 
marking the transcript for degradation (Jin et al. 2011).  MiRNAs are transcribed by RNA 
polymerase II as normal mRNAs are, and can be expressed as an independent transcript 
or as the intron of another gene (Howell et al. 2010).  After transcription, the miRNA is 
processed just like any other mRNA transcript would be (Jin et al. 2011) but before 
exiting the nucleus, the excess 3’ and 5’ ends are cleaved to form a seventy nucleotide 
long hairpin loop by the RNase III-type endonuclease Drosha and its cofactor Pasha 
(DGCR8) (Howell et al. 2010).  The precursor miRNA is then transported from the 
nucleus to the cytoplasm, where it binds to the RNase III-type endonuclease DICER 
(Howell et al. 2010).  DICER cleaves the precursor miRNA producing two 
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complementary mature miRNA transcripts, one of which will be degraded (Howell et al. 
2010).  The other mature miRNA will bind to the RNA-induced silencing complex 
(RISC) which guides the miRNA to its target mRNA (Howell et al. 2010).   
The role of miRNA in cancer is not well understood as of yet, particularly in 
melanoma, but recent research has identified multiple miRNA molecules that may aid in 
melanoma onset (Howell et al. 2010).  For example, miRNA-137 (miR-137) and miR-
182 have been shown to negatively regulate the expression of the melanoma oncogene 
microphthalmia-associated transcription factor (MITF) (Howell et al. 2010).  Further 
research into miR-182 revealed that it is overexpressed in some human melanomas, 
which can lead to increased invasion and survival of melanoma cells (Howell et al. 2010).  
Not all miRNAs act to promote tumorigenesis but some actually may function as tumor 
suppressors (Howell et al. 2010).  Such is the case with miR-34, which has been found to 
be dysregulated in melanoma, and was recently identified as an effector for the tumor 
suppressor p53 (Howell et al. 2010).  Experiments showed that the pairing of p53 and 
miR-34 lead to increased G1 cell cycle arrest and apoptosis (Howell et al. 2010).  In 
conclusion, the role of miRNA in melanoma is vast, varying, complex and only recently 
beginning to be unraveled.  
Epigenetics is an emerging field in genetics and promises to be the future of 
personalized medicine.  However, many obstacles stand in the way of an actual therapy 
being developed, one of which is time. 
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Future Considerations 
Much progress has been made in understanding the origin(s) of acquired BRAF 
inhibitor resistance.  However, given the prevalence of oncogenic BRAF in melanoma, 
much research remains to be done in this area.  Recently, the next generation of BRAF 
inhibitors was revealed that can seemingly prevent activated MAPK signaling (Smalley 
and McArthur 2012).  Although research on these new compounds is lacking (Smalley 
and McArthur 2012), their discovery is an encouraging development for the treatment of 
melanoma. 
Hybrid compounds that are able to target both the MAPK and PI3K/AKT 
simultaneously have already been demonstrated to be effective in other types of cancer, 
such as breast cancer, and have been proposed, but not yet tested, as treatments for 
melanoma.  One of these compounds is tamoxifen which is a protein kinase C (PKC) 
inhibitor that is already in use for the treatment of breast cancer (Matsuoka et al. 2009).  
PKC is a kinase that activates upstream effectors of the MAPK and PI3K/AKT pathways, 
thus, if it is inhibited, one mechanism by which ERK and AKT are activated is repressed 
(Matsuoka et al. 2009).  Use of this compound in mice injected with melanoma cells has 
shown a decrease in cell migration, invasion and metastasis through decreased activation 
of ERK and AKT (Matsuoka et al. 2009).  A similar drug is hexamethylene bisacetamide 
(HMBA) which is a hybrid polar compound that also inhibits both the MAPK and 
PI3K/AKT pathways (Dey et al. 2008, Madhunapantula and Robertson 2011).  HMBA 
has shown promising results in inducing apoptosis in breast cancer, myeloma, 
hepatocellular carcinoma, T acute lymphoblastic leukemia (T-ALL) and acute myeloid 
leukemia (AML) cells, and given its molecular effects, could be a potential effective 
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treatment for metastatic melanoma (Dey et al. 2008, Madhunapantula and Robertson 
2011). 
Three different isoforms of AKT exist: AKT1, AKT2 and AKT3 
(Madhunapantula and Robertson 2011).  Activating mutations of all three isoforms have 
been observed in different types of cancer with AKT1 activation observed in breast, 
colorectal, endometrial and ovarian cancers, AKT2 seen in ovarian, colorectal and 
pancreatic cancers and AKT3 in melanoma (Courtney et al. 2010, Madhunapantula and 
Robertson 2011).  Despite a shared 80% homology, each isoform has a different function 
from the rest and not much is known of regulation mechanisms behind the specific 
functions (Madhunapantula and Robertson 2011).  Recent evidence found mutations in 
AKT3 that allow it to be recruited to PDK1 in the plasma membrane independent of PIP3 
binding and thus PI3K activity (Madhunapantula and Robertson 2009).  Also, AKT3 was 
found to be overexpressed in melanoma cells due to copy number increase of 
chromosome one where the AKT3 gene is located, but no such copy number variations 
were found in the chromosomes of the AKT1 and AKT2 genes (Madhunapantula and 
Robertson 2009).  Other theories that could possibly explain why AKT3 has been 
connected to melanoma and not the other two AKT isoforms is that PTEN loss leads to 
preferential AKT3 activation and favored phosphorylation of the PH domain of AKT3 by 
accessory proteins (Madhunapantula and Robertson 2009).  Further research into the 
mechanisms behind  AKT3 overactivation in melanoma and the specific function of each 
isoform could help lead to  new avenues of understanding the molecular basis of the 
disease and new therapeutic targets, not just for melanoma, but also for cancers in which 
other AKT isoforms have been implicated. 
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AKT3 is eventually dephosphorylated thus deactivating its phosphorylation 
activity by protein phosphatase 2A (PP2A) and PH domain leucine rich repeat protein 
phosphatase (PHLPP) (Madhunapantula and Robertson 2011).  The role that these two 
proteins play in melanoma development is not known at this time (Madhunapantula and 
Robertson 2011).  However, given their ability to deactivate AKT3, it would stand to 
reason that loss of these proteins could be involved in melanomagenesis and could be 
targeted for therapeutic benefit. 
Prior strategies for targeting oncogenic mutations in melanoma included treating 
all melanomas with targeted agents irrespective of tumor genotype.  However, every 
patient’s tumor genotype is different.  Therefore, it is imperative to identify a patient’s 
mutational status in order to determine which pharmaceuticals and which pharmaceutical 
combinations would be most beneficial for the patient.  Vidwans et al. (2011) proposed a 
molecular model of melanoma in which tumors are classified into subtypes depending on 
which genes are altered.  The treatment that a patient receives would depend on which 
subtype their tumor fell into, making it easier for physicians everywhere to have a 
somewhat standard strategy for treatment.  For example, based on the model, if a patient 
had alteration in the BRAF and CDK4 genes, they would receive BRAF and CDK4 
inhibitors in conjunction to ensure that both oncogenic pathways were inhibited.  
However, given the ever changing landscape of cancer research and development, a 
molecular disease model may become obsolete rather quickly, therefore, making it 
difficult to standardize treatment. 
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Conclusion 
Melanoma is a type of skin cancer that originates in melanocytes, cells that 
produce the pigment melanin.  If diagnosed and treated early, the five year survival rate is 
especially high.  However, metastatic melanoma is especially lethal and is the most 
deadly of all types of skin cancer.  Incidence rates are on the rise, especially in young 
people, most likely due to natural or artificial ultraviolet light exposure. 
The leading genes that are found to be mutated in melanoma, v-Raf murine 
sarcoma viral oncogene homolog B1 (BRAF), neuroblastoma RAS viral (v-ras) oncogene 
homolog (NRAS), Phosphatase and tensin homolog deleted on chromosome ten (PTEN) 
and cyclin dependent kinase inhibitor 2A (CDKN2A), belong to the MAPK (Mitogen-
activated protein kinase/Extracellular signal-regulated kinases) pathway, the 
phosphoinositide 3’ kinase (PI3K)/AKT pathway or the INK4/ARF locus which together 
form a signaling network that work in tandem to promote cell proliferation, migration, 
invasion and metastasis.  Recent advances have been made in molecular targeted therapy, 
such as BRAF inhibitors, but tumor regrowth is often seen after treatment has ended.  
Therefore, recent research has focused on understanding the reasons behind acquired 
BRAF inhibitor resistance, and much of the evidence points toward continued activation 
of the MAPK and PI3K/AKT pathways through BRAF independent routes.  Innovative 
treatments, consequently, have focused on combining already existing treatments that 
target both pathways.  Great progress has been seen in clinical trials with these 
combination treatments, but there is still a long road to go before combination treatments 
will be widely used.  Epigenetics, which includes DNA methylation, histone 
modifications and non-coding RNAs, is a promising field in cancer research that can 
 41 
offer insight into causes and personalized treatments.  However, much work remains to 
be done when it comes to understanding the consequences of altering epigenetic markers 
that have led to cancer; thus, treatments targeting epigenetic causes of cancer are a long 
term goal.  Therefore, for the foreseeable future, the promise of new treatments for 
melanoma lies with simultaneously targeting signaling pathways, such as the MAPK and 
PI3K/AKT pathways, that have already been implicated in melanomagenesis. 
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